Lv5
888 积分 2026-04-01 加入
Induction Immune Checkpoint Inhibitors and Chemotherapy Before Definitive Chemoradiation Therapy for Patients With Bulky Unresectable Stage III Non-Small Cell Lung Cancer
1分钟前
待确认
The chemo-free approach for PDL1-positive platinum-sensitive recurrent/metastatic head and neck squamous cell carcinoma: Viable option or misguided myth?
8天前
已完结
Neoadjuvant vs perioperative chemo-immunotherapy according to pathological response in resectable non-small cell lung cancer: a reconstructed individual patient data meta-analysis
8天前
已完结
Prognostic dynamics of pathological complete response and circulating tumor DNA clearance after neoadjuvant and perioperative immunotherapy in cancer: a reconstructed individual patient analysis
8天前
已完结
Socioeconomic disparity in mortality and the burden of cardiovascular disease: analysis of the Prospective Urban Rural Epidemiology (PURE)-China cohort study
10天前
已完结
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
13天前
已完结
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
14天前
已完结
Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study
14天前
已完结
Characterizing Spin in Psychiatric Clinical Research Literature Using Large Language Models
1个月前
已完结
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
